# Temsirolimus-RCC-imaging

> **NCT01246817** · PHASE2 · UNKNOWN · sponsor: **Radboud University Medical Center** · enrollment: 51 (estimated)

## Conditions studied

- Renal Cell Cancer

## Interventions

- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01246817
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-08
- **Primary completion:** 2012-08
- **Final completion:** —
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2012-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01246817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01246817, "Temsirolimus-RCC-imaging". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01246817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*